Date: 2016-11-15
Type of information: Nomination
Compound: chief scientific officer
Company: Rigontec (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 15, 2016, Rigontec announced that Dr. Jörg Vollmer has joined the company as Chief Scientific Officer. Dr. Vollmer brings to Rigontec more than 17 years of drug discovery and development experience including leadership roles at Nexigen, Pfizer and Coley Pharmaceutical Group. Dr. Vollmer will be responsible for leading Rigontec’s R&D efforts and advancing the Company’s RIG-I-based platform focused on discovering and developing treatments for oncological and infectious diseases. He will report to Dr. Christian Schetter, CEO of Rigontec, and will be based in Munich.
- Most recently, Dr. Vollmer was CEO and Managing Director at Nexigen developing cell penetrating peptide therapeutics targeting tumor stem cell signaling pathways. Prior to this, he held the positon of Managing Director and Site Head at Pfizer’s Oligonucleotide Therapeutics Unit in Düsseldorf, Germany where he was responsible for therapeutic oligonucleotide research. Dr. Vollmer started his career at Coley Pharmaceutical Group where he focused on the development of immune modulatory oligonucleotides targeting Toll-like receptors, and held several positions leading up to Vice President Discovery & Development before the company was acquired by Pfizer in 2008. Upon the acquisition he refocused Coley Pharmaceutical’s Düsseldorf site towards gene knock-down and transcriptional gene silencing technologies including RNA interference and antisense technologies and their formulation and delivery. Dr. Vollmer studied biology at the Albert-Ludwigs-University in Freiburg and received a Ph.D. from the Max-Planck-Institute of Immunobiology at the Department for Cellular Immunology in Freiburg, Germany.
Financial terms:
Latest news:
Is general: Yes
